<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Aqr International Multi-style Fund Class I — News on 6ix</title>
    <link>https://6ix.com/company/aqr-international-multi-style-fund-class-i</link>
    <description>Latest news and press releases for Aqr International Multi-style Fund Class I on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 21 Apr 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/aqr-international-multi-style-fund-class-i" rel="self" type="application/rss+xml" />
    <item>
      <title>Zurn Elkay Water Solutions Reports First Quarter 2026 Financial Results</title>
      <link>https://6ix.com/company/aqr-international-multi-style-fund-class-i/news/zurn-elkay-water-solutions-reports-first-quarter-2026-financial-results-7</link>
      <guid isPermaLink="true">https://6ix.com/company/aqr-international-multi-style-fund-class-i/news/zurn-elkay-water-solutions-reports-first-quarter-2026-financial-results-7</guid>
      <pubDate>Tue, 21 Apr 2026 04:00:00 GMT</pubDate>
      <description>Investor call scheduled for Wednesday, April 22, 2026 at 8:30 a.m. Eastern Time MILWAUKEE--(BUSINESS WIRE)-- Zurn Elkay Water Solutions Corporation</description>
    </item>
    <item>
      <title>Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting</title>
      <link>https://6ix.com/company/aqr-international-multi-style-fund-class-i/news/black-diamond-therapeutics-announces-oral-presentation-of-silevertinib-phase-2-data-in-frontline-egfrm-nsclc-patients-at-the-2026-asco-annual-meeting-2</link>
      <guid isPermaLink="true">https://6ix.com/company/aqr-international-multi-style-fund-class-i/news/black-diamond-therapeutics-announces-oral-presentation-of-silevertinib-phase-2-data-in-frontline-egfrm-nsclc-patients-at-the-2026-asco-annual-meeting-2</guid>
      <pubDate>Tue, 21 Apr 2026 04:00:00 GMT</pubDate>
      <description>Poster also to be presented on the Phase 2 data of silevertinib in recurrent EGFRm NSCLC patients Trial-in-progress poster to be presented on the randomized</description>
    </item>
  </channel>
</rss>